AV-101 (VistaGen Therapeutics)

N/A

Report date: 2025/05/09 15:54:10
NME

Base Information

Drug NameAV-101 (VistaGen Therapeutics)
Drug Alias NameL-4-Chlorokynurenine4-ChlorokynurenineAV-1014-Cl-KYNL-4-CL-KYN +[6] 
ClassificationSmall molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonistsKynurenine modulators
TargetsGlutamate [NMDA] receptorKynurenine
Therapy Area/IndicationsDepressive Disorder, MajorDrug-Related Side Effects and Adverse ReactionsNeuralgia +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArtemis Neuroscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVistagen Therapeutics IncNational Institute Of Mental Health (Nimh)
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, MajorDrug-Related Side Effects and Adverse ReactionsNeuralgia +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank